ArticleDiscover oncology2026
Integrating multiomics data using a correlation based graph attention network for subtype classification in lower grade glioma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Accurate classification of cancer subtypes is crucial for personalised therapies and targeted interventions. In this study, we propose BioGAT-LGG, a deep learning framework that integrates multi-omics data, including mRNA, miRNA, and DNA methylation, using a correlation-based Graph Attention Network version 2 (GATv2) for biomarker discovery and Lower-Grade Glioma (LGG) subtype classification. Unlike existing methodologies that rely on external biological priors, such as protein-protein interaction networks or reference graphs, BioGAT-LGG constructs gene-driven correlation graphs, enabling the model to learn biologically meaningful molecular interactions. To improve feature interpretability and reduce dimensionality, LASSO regression is performed during model training. The model achieved 98.03% accuracy, with precision (98.12%), recall (97.74%), and F1-score (97.87%) in a stratified 10-fold cross-validation. Extensive analysis and enrichment of known cancer-related pathways, including PI3K-Akt signalling, Small Cell Lung Cancer, and Transcriptional Misregulation in Cancer, identified the biomarkers hsa-mir-3936, MTCO1P40, and CCND2, which were subsequently validated. These results indicate that BioGAT-LGG effectively captures biologically validated mechanisms and can enable clinically significant subtype classification and biomarker-guided decision-making. This framework thus lays a scalable foundation for multi-omics integration in oncology, which can be further adopted in other tumour types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.